William Doyle - Zoetis Director

ZTS -- USA Stock  

USD 122.42  2.78  2.32%

  Director
Mr. William F. Doyle is Independent Director of Company. Mr. Doyle is Member of Pershing Square Capital Management L.P., a registered investment advisor, since 2013, where he serves as a senior advisor focused on the healthcare industry. Since 2003, Mr. Doyle was the Managing Partner of WFD Ventures LLC, an investor in earlystage human healthcare device, drug and service companies. Previously, as an executive at Johnson Johnson, Mr. Doyle was a member of Johnson Johnsons Consumer Pharmaceuticals and Medical Devices Group Operating Committee with responsibility for licensing, acquisitions and strategy. He was also Chairman of Johnson Johnsons Medical Devices Research and Development Council, Worldwide President of BiosenseWebster, and a member of the internal boards of directors of Cordis Corporationrationration and Johnson Johnson Development Corporationrationration . Earlier, Mr. Doyle was a management consultant with McKinsey Co. working in McKinseys Global Healthcare practice group. Mr. Doyle serves as chairman of the board of Novocure Ltd., a public company since October 2, 2015, that is commercializing a new therapeutic modality for glioblastoma and other solid tumors and is a member of the boards of several private companies, including Optinose, Inc., a developer of new therapies for migraine, nasal inflammatory disease and autism. In addition, Mr. Doyle is a member of the Deans Board of Advisors of Harvard Business School Harvard Business Schools Healthcare Advisory Board and the MIT Corporationrationrations visiting committee for undergraduate education
Age: 52  Director Since 2015  MBA    
973-822-7000  http://www.zoetis.com
Doyle holds a bachelor?s degree in materials science and engineering from the Massachusetts Institute of Technology and an MBA from Harvard Business School.

William Doyle Latest Insider Activity

William Doyle over three months ago via Macroaxis 
Sale by William Doyle of 1900 shares of NovoCure

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Herman MorrisPerrigo Company plc
1999
Fei WangOrigin Agritech Limited
2019
Michael BrownRegeneron Pharmaceuticals
1991
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Bruce CarterDr Reddys Laboratories Ltd
2008
Michael TrimbleOrigin Agritech Limited
2006
Geoffery MerszeiOrigin Agritech Limited
2016
Theodore SamuelsPerrigo Company plc
2017
Prasad MenonDr Reddys Laboratories Ltd
2019
Joseph GoldsteinRegeneron Pharmaceuticals
1991
Anthony ColesRegeneron Pharmaceuticals
2017
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Allan ObermanDr Reddys Laboratories Ltd
2019
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
David BullockOrigin Agritech Limited
2015
Yingqi XiaOrigin Agritech Limited
2010
James KangOrigin Agritech Limited
2010
Bradley AlfordPerrigo Company plc
2017
Jacqualyn FousePerrigo Company plc
2012
Shlomo YanaiPerrigo Company plc
N/A
Alan GarberVertex Pharmaceuticals Incorpor
2017

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Current Sentiment - ZTS

Zoetis Investor Sentiment

Greater number of Macroaxis users are at this time bullish on Zoetis. What is your take regarding investing in Zoetis? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Also Currentnly Active

Purchased over 300 shares of
few hours ago
Traded for 35.11
Sold over 200 shares of
few hours ago
Traded for 47.76
Purchased over 100 shares of
few hours ago
Traded for 4.78
See also Your Current Watchlist. Please also try My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Search macroaxis.com